DARPP-32 can enhance the interaction between EGFR and ERBB3, thereby activating the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway and promoting resistance to gefitinib in gastric cancer cells [102]. Here, EGFR is linked to gastric cancer.